Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Characteristics and management of primary gastrointestinal non-Hodgkin's lymphoma

A uniform reporting system for primary gastrointestinal non-Hodgkin's lymphoma is needed to facilitate comparison of treatment results, according to research in the latest Journal of Clinical Oncology.

News image

fiogf49gjkf04

Researchers from Germany conducted two studies, in which they investigated the characteristics and management of patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL), between 1992 and 1996.

In the first, they obtained epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in 371 patients with PGI NHL.

Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.

Of the patients, 75% had gastric NHL. Within the intestine, the small bowel and the ileocecal region were involved in 9% and 7% of the cases, respectively. Multiple GI involvement was 6.5%.

Approximately 90% of the GI NHL were in stages IE/IIE.

Aggressive NHL accounted for the majority, with a distinguishable pattern in several sites.

40% of PGL were of low-grade mucosa-associated lymphatic tissue type. One third of large-cell lymphomas had low-grade components. Most intestinal NHL were germinal-center lymphomas.

In gastric and ileocecal lymphoma, event-free and overall survival were significantly higher, as compared with the small intestine or multiple GI involvement.

In PGL, localized disease was prognostic for both event-free and overall survival. However, histologic grade only influenced event-free survival significantly.

The authors commented that PGI NHL are heterogeneous diseases. The number of localized PGL allowed the investigators to conduct detailed analyses, although larger studies are needed for stages III and IV, and for intestinal NHL.

A uniform reporting system for PGI NHL, in terms of definitions, and histologic and staging classifications, is needed to facilitate comparison of treatment results, they concluded.

5-year survival rates after PGI NHL treatment:
Conservative treatment 84%
Conservative treatment plus surgery 85%
Journal of Clinical Oncology

In the second study, the team focused on the combined surgical and conservative treatment (CSCT) versus conservative treatment (CT) alone for localized gastric lymphoma.

Patients with low-grade PGL were treated with extended-field (EF) radiotherapy (30 Gy).

In case of residual tumor after surgery or in case of CT only (in stage IIE after 6 cycles of cyclophosphamide, vincristine, and prednisone), an additional boost of 10 Gy was given.

All patients with high-grade PGL were treated with 4 (stage IE) or 6 (stage IIE) cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone. This was followed by EF radiotherapy (stage IE) or involved-field (IF) radiotherapy (stage IIE).

Radiotherapy dosage corresponded to low-grade NHL.

A total of 106 patients had CT only. The survival rate after 5 years was found to be 84%. It was influenced neither by patients' characteristics nor by stage or histologic grade.

Some 79 patients had CSCT. Their survival rate was 82%.

The team found that complete resection of the tumor was prognostic for the overall survival, as compared with incomplete resection.

Dr Peter Koch, of Münster, Germany, concluded on behalf of the group, "Although the study was not randomized, a stomach-conserving approach may be favored."

J Clin Oncol 2001; 19 (18): 3861-83
20 September 2001

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us